GlaxoSmithKline: Virus Diseases trials

The registry lists 20 Virus Diseases studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 14 have results posted.

Phase 1 4Phase 2 8Phase 3 3Phase 4 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1CompletedNCT06214052Phase 2Results posted
• A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult ParticipantsCompletedNCT06058390Phase 1Results posted
• A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy AdultsCompletedNCT04758962Phase 1Results posted
• The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults VaccineCompletedNCT03294135Phase 4Results posted
• Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With InfluenzaTerminatedNCT02927431Phase 2Results posted
• A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in ChildrenCompletedNCT02548078Phase 2Results posted
• A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis.CompletedNCT02545517Phase 3Results posted
• A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in AdultsCompletedNCT02485301Phase 2Results posted
• Safety, Tolerability and Clinical Effect of Danirixin in Adults With InfluenzaCompletedNCT02469298Phase 2Results posted
• Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination SchedulesCompletedNCT01562444Phase 4Results posted
• Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the ControlCompletedNCT00778895Phase 2Results posted
• Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 YrsCompletedNCT00541970Phase 1Results posted
• Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of AgeCompletedNCT00492544Phase 3Results posted
• Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of AgeCompletedNCT00423046Phase 3Results posted
• A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and AboveCompletedNCT07204964Phase 2
• A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and OlderCompletedNCT07121192Phase 2
• A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy AdultsCompletedNCT04062669Phase 1
• A Study to Evaluate the One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens in Chinese ChildrenWithdrawnNCT03192371Phase 4
• A Study to Evaluate Persistence of Immune Responses After Post-exposure Prophylaxis of Rabipur® (Purified Chicken-embryo Cell Rabies Vaccine) in Chinese ChildrenCompletedNCT02991872Phase 4
• Pharmacokinetic Study Of Valaciclovir Hydrochloride TabletsCompletedNCT00343278Phase 4